Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferrous fumarate is an anhydrous iron(II) salt of fumaric acid, widely utilized as an oral iron supplement for the treatment and prevention of iron deficiency anemia. It provides a high concentration of elemental iron (approximately 33% by weight), which is essential for the synthesis of hemoglobin and myoglobin. In clinical practice, it is frequently used as a standard oral comparator for newer intravenous iron formulations like ferumoxytol and ferric carboxymaltose, particularly in patients with chronic kidney disease (CKD) or inflammatory bowel disease (IBD). However, its clinical utility can be limited by gastrointestinal side effects and impaired absorption in specific populations, such as those who have undergone Roux-en-Y gastric bypass (RYGB). Furthermore, in patients with active IBD, oral ferrous fumarate may exacerbate intestinal inflammation by promoting the production of reactive oxygen species.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferrous fumarate.